Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 733 to 740 of 740 entries
Sorted by: Best Match Show Resources per page
In vitro interaction of potential antiviral TMPRSS2 inhibitors with human serum albumin and cytochrome P 450 isoenzymes.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Pászti-Gere E, Szentkirályi A, Fedor Z, Nagy G, Szimrók Z, Pászti Z, Pászti A, Pilgram O, Steinmetzer T, Bodnárová S, Fliszár-Nyúl E, Poór M.
PMID: 34915414
Biomed Pharmacother. 2021 Dec 13;146:112513. doi: 10.1016/j.biopha.2021.112513. Epub 2021 Dec 13.

The interactions of four sulfonylated Phe(3-Am)-derived inhibitors (MI-432, MI-463, MI-482 and MI-1900) of type II transmembrane serine proteases (TTSP) such as transmembrane protease serine 2 (TMPRSS2) were examined with serum albumin and cytochrome P450 (CYP) isoenzymes. Complex formation with...

Cite
Pászti-Gere E, Szentkirályi A, Fedor Z, et al. In vitro interaction of potential antiviral TMPRSS2 inhibitors with human serum albumin and cytochrome P 450 isoenzymes. Biomed Pharmacother. 2021;146:112513doi: 10.1016/j.biopha.2021.112513.
Pászti-Gere, E., Szentkirályi, A., Fedor, Z., Nagy, G., Szimrók, Z., Pászti, Z., Pászti, A., Pilgram, O., Steinmetzer, T., Bodnárová, S., Fliszár-Nyúl, E., & Poór, M. (2021). In vitro interaction of potential antiviral TMPRSS2 inhibitors with human serum albumin and cytochrome P 450 isoenzymes. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112513. https://doi.org/10.1016/j.biopha.2021.112513
Pászti-Gere, Erzsébet, et al. "In vitro interaction of potential antiviral TMPRSS2 inhibitors with human serum albumin and cytochrome P 450 isoenzymes." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112513. doi: https://doi.org/10.1016/j.biopha.2021.112513
Pászti-Gere E, Szentkirályi A, Fedor Z, Nagy G, Szimrók Z, Pászti Z, Pászti A, Pilgram O, Steinmetzer T, Bodnárová S, Fliszár-Nyúl E, Poór M. In vitro interaction of potential antiviral TMPRSS2 inhibitors with human serum albumin and cytochrome P 450 isoenzymes. Biomed Pharmacother. 2021 Dec 13;146:112513. doi: 10.1016/j.biopha.2021.112513. Epub 2021 Dec 13. PMID: 34915414; PMCID: PMC8668183.
Copy Download .nbib Format: NLM
Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter.

Toxicology and applied pharmacology

Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J.
PMID: 34896433
Toxicol Appl Pharmacol. 2021 Dec 09;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 09.

Alisertib (MLN8237), a novel Aurora A kinase inhibitor, is currently being clinically tested in late-phase trials for the therapy of various malignancies. In the present work, we describe alisertib's potential to perpetrate pharmacokinetic drug-drug interactions (DDIs) and/or to act...

Cite
Vagiannis D, Zhang Y, Budagaga Y, et al. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol. 2021;434:115823doi: 10.1016/j.taap.2021.115823.
Vagiannis, D., Zhang, Y., Budagaga, Y., Novotna, E., Skarka, A., Kammerer, S., Küpper, J. H., & Hofman, J. (2021). Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicology and applied pharmacology, 434115823. https://doi.org/10.1016/j.taap.2021.115823
Vagiannis, Dimitrios, et al. "Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter." Toxicology and applied pharmacology vol. 434 (2021): 115823. doi: https://doi.org/10.1016/j.taap.2021.115823
Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol. 2021 Dec 09;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 09. PMID: 34896433.
Copy Download .nbib Format: NLM
Arginine Therapy for Lung Diseases.

Frontiers in pharmacology

Scott JA, Maarsingh H, Holguin F, Grasemann H.
PMID: 33833679
Front Pharmacol. 2021 Mar 23;12:627503. doi: 10.3389/fphar.2021.627503. eCollection 2021.

Nitric oxide (NO) is produced by a family of isoenzymes, nitric oxide synthases (NOSs), which all utilize L-arginine as substrate. The production of NO in the lung and airways can play a number of roles during lung development, regulates...

Cite
Scott JA, Maarsingh H, Holguin F, et al. Arginine Therapy for Lung Diseases. Front Pharmacol. 2021;12:627503doi: 10.3389/fphar.2021.627503.
Scott, J. A., Maarsingh, H., Holguin, F., & Grasemann, H. (2021). Arginine Therapy for Lung Diseases. Frontiers in pharmacology, 12627503. https://doi.org/10.3389/fphar.2021.627503
Scott, Jeremy A, et al. "Arginine Therapy for Lung Diseases." Frontiers in pharmacology vol. 12 (2021): 627503. doi: https://doi.org/10.3389/fphar.2021.627503
Scott JA, Maarsingh H, Holguin F, Grasemann H. Arginine Therapy for Lung Diseases. Front Pharmacol. 2021 Mar 23;12:627503. doi: 10.3389/fphar.2021.627503. eCollection 2021. PMID: 33833679; PMCID: PMC8022134.
Copy Download .nbib Format: NLM
Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter.

Toxicology and applied pharmacology

Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J.
PMID: 34896433
Toxicol Appl Pharmacol. 2021 Dec 09;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 09.

Alisertib (MLN8237), a novel Aurora A kinase inhibitor, is currently being clinically tested in late-phase trials for the therapy of various malignancies. In the present work, we describe alisertib's potential to perpetrate pharmacokinetic drug-drug interactions (DDIs) and/or to act...

Cite
Vagiannis D, Zhang Y, Budagaga Y, et al. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol. 2021;434:115823doi: 10.1016/j.taap.2021.115823.
Vagiannis, D., Zhang, Y., Budagaga, Y., Novotna, E., Skarka, A., Kammerer, S., Küpper, J. H., & Hofman, J. (2021). Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicology and applied pharmacology, 434115823. https://doi.org/10.1016/j.taap.2021.115823
Vagiannis, Dimitrios, et al. "Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter." Toxicology and applied pharmacology vol. 434 (2021): 115823. doi: https://doi.org/10.1016/j.taap.2021.115823
Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol. 2021 Dec 09;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 09. PMID: 34896433.
Copy Download .nbib Format: NLM
Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment.

Journal of research in pharmacy practice

Keche Y, Gaikwad N, Dhaneria S, Joshi A.
PMID: 33912505
J Res Pharm Pract. 2021 Jan 11;9(4):212-217. doi: 10.4103/jrpp.JRPP_20_107. eCollection 2020.

OBJECTIVE: Earlier identifying drug interactions may help in risk reduction in elderly patients.METHODS: Drug prescription data of 212 elderly patients of tertiary health care center had been analyzed for possible drug interactions with investigational drugs for COVID-19 treatment. Drug...

Cite
Keche Y, Gaikwad N, Dhaneria S, et al. Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment. J Res Pharm Pract. 2021;9(4):212-217doi: 10.4103/jrpp.JRPP_20_107.
Keche, Y., Gaikwad, N., Dhaneria, S., & Joshi, A. (2020). Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment. Journal of research in pharmacy practice, 9(4), 212-217. https://doi.org/10.4103/jrpp.JRPP_20_107
Keche, Yogendra, et al. "Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment." Journal of research in pharmacy practice vol. 9,4 (2020): 212-217. doi: https://doi.org/10.4103/jrpp.JRPP_20_107
Keche Y, Gaikwad N, Dhaneria S, Joshi A. Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment. J Res Pharm Pract. 2021 Jan 11;9(4):212-217. doi: 10.4103/jrpp.JRPP_20_107. eCollection 2020. PMID: 33912505; PMCID: PMC8067896.
Copy Download .nbib Format: NLM
Discovery of sulfadrug-pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors.

Archiv der Pharmazie

Gümüş M, Babacan ŞN, Demir Y, Sert Y, Koca İ, Gülçin İ.
PMID: 34609760
Arch Pharm (Weinheim). 2021 Oct 05;e2100242. doi: 10.1002/ardp.202100242. Epub 2021 Oct 05.

Human carbonic anhydrase (hCA) isoenzymes are zinc ion-containing, widespread metalloenzymes and they classically play a role in pH homeostasis maintenance. CA inhibitors suppress the CA activity and their usage has been clinically established as antiglaucoma agents, antiepileptics, diuretics, and...

Cite
Gümüş M, Babacan ŞN, Demir Y, et al. Discovery of sulfadrug-pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors. Arch Pharm (Weinheim). 2021;e2100242doi: 10.1002/ardp.202100242.
Gümüş, M., Babacan, �. �. N., Demir, Y., Sert, Y., Koca, �. �., & Gülçin, �. �. (2021). Discovery of sulfadrug-pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors. Archiv der Pharmazie, e2100242. https://doi.org/10.1002/ardp.202100242
Gümüş, Mehmet, et al. "Discovery of sulfadrug-pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors." Archiv der Pharmazie vol. (2021): e2100242. doi: https://doi.org/10.1002/ardp.202100242
Gümüş M, Babacan ŞN, Demir Y, Sert Y, Koca İ, Gülçin İ. Discovery of sulfadrug-pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors. Arch Pharm (Weinheim). 2021 Oct 05;e2100242. doi: 10.1002/ardp.202100242. Epub 2021 Oct 05. PMID: 34609760.
Copy Download .nbib Format: NLM
Paradoxical Reactions to Midazolam in a Term Parturient After Intravenous Sedation During Cesarean Section.

Cureus

Sivakumar S, Mendonca R, Demeterio D, Girshin M.
PMID: 34513535
Cureus. 2021 Sep 03;13(9):e17678. doi: 10.7759/cureus.17678. eCollection 2021 Sep.

Propofol and midazolam are commonly used drugs in procedural sedation. Midazolam is widely used for its five principal pharmacologic effects: anxiolysis, sedation and hypnosis, anticonvulsant actions, spinal cord-mediated skeletal muscle relaxation, and anterograde amnesia. Increased talkativeness, emotional release, excitement,...

Cite
Sivakumar S, Mendonca R, Demeterio D, et al. Paradoxical Reactions to Midazolam in a Term Parturient After Intravenous Sedation During Cesarean Section. Cureus. 2021;13(9):e17678doi: 10.7759/cureus.17678.
Sivakumar, S., Mendonca, R., Demeterio, D., & Girshin, M. (2021). Paradoxical Reactions to Midazolam in a Term Parturient After Intravenous Sedation During Cesarean Section. Cureus, 13(9), e17678. https://doi.org/10.7759/cureus.17678
Sivakumar, Sengottaian, et al. "Paradoxical Reactions to Midazolam in a Term Parturient After Intravenous Sedation During Cesarean Section." Cureus vol. 13,9 (2021): e17678. doi: https://doi.org/10.7759/cureus.17678
Sivakumar S, Mendonca R, Demeterio D, Girshin M. Paradoxical Reactions to Midazolam in a Term Parturient After Intravenous Sedation During Cesarean Section. Cureus. 2021 Sep 03;13(9):e17678. doi: 10.7759/cureus.17678. eCollection 2021 Sep. PMID: 34513535; PMCID: PMC8415540.
Copy Download .nbib Format: NLM
Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra.

Research and reports in urology

Rahardjo HE, Ückert S, Bannowsky A, Kuczyk MA, Kedia GT.
PMID: 33777854
Res Rep Urol. 2021 Mar 19;13:139-145. doi: 10.2147/RRU.S291962. eCollection 2021.

PURPOSE: Although it has been supposed that the NO/cyclic GMP system produces inhibitory signals to reduce the resistance of the bladder outlet and urethra during the micturition phase, little is known on the mechanisms controlling the function of urethral...

Cite
Rahardjo HE, Ückert S, Bannowsky A, et al. Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra. Res Rep Urol. 2021;13:139-145doi: 10.2147/RRU.S291962.
Rahardjo, H. E., Ückert, S., Bannowsky, A., Kuczyk, M. A., & Kedia, G. T. (2021). Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra. Research and reports in urology, 13139-145. https://doi.org/10.2147/RRU.S291962
Rahardjo, Harrina E, et al. "Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra." Research and reports in urology vol. 13 (2021): 139-145. doi: https://doi.org/10.2147/RRU.S291962
Rahardjo HE, Ückert S, Bannowsky A, Kuczyk MA, Kedia GT. Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra. Res Rep Urol. 2021 Mar 19;13:139-145. doi: 10.2147/RRU.S291962. eCollection 2021. PMID: 33777854; PMCID: PMC7989682.
Copy Download .nbib Format: NLM
Showing 733 to 740 of 740 entries